STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.-论文-万方医学网

作者： Raghvendra M,Srivastava ^[1] ; Sumita,Trivedi ^[1] ; Fernando,Concha-Benavente ^[2] ; Jie,Hyun-Bae ^[1] ; Lin,Wang ^[1] ; Raja R,Seethala ^[3] ; Barton F,Branstetter ^[4] ; Soldano,Ferrone ^[5] ; Robert L,Ferris ^[6]

作者单位： Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. ^[1] Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania. ^[2] Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania. ^[3] Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania. ^[4] Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ^[5] Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania. Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. ferrisrl@upmc.edu. ^[6]

主题词成年人(Adult);老年人(Aged);等位基因(Alleles);抗原呈递(Antigen Presentation);抗原, 肿瘤(Antigens, Neoplasm);抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);女(雌)性(Female);基因表达(Gene Expression);头颈部肿瘤(Head and Neck Neoplasms);组织相容性抗原Ⅰ类(Histocompatibility Antigens Class I);人类(Humans);免疫调节(Immunomodulation);杀伤细胞, 天然(Killer Cells, Natural);男(雄)性(Male);中年人(Middle Aged);肿瘤辅助疗法(Neoadjuvant Therapy);蛋白质酪氨酸磷酸酶, 非受体11型(Protein Tyrosine Phosphatase, Non-Receptor Type 11);受体, 干扰素(Receptors, Interferon);STAT1转录因子(STAT1 Transcription Factor);信号传导(Signal Transduction);治疗结果(Treatment Outcome)

DOI 10.1158/2326-6066.CIR-15-0053

PMID 25972070

发布时间 2022-04-08

检索历史清除

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Cancer immunology research

相似文献

Cancer immunology research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Cancer immunology research

相似文献

Cancer immunology research

相关期刊

检索历史清除